137 related articles for article (PubMed ID: 38867457)
1. Mucoadhesive Mesalamine Prodrug Nanoassemblies to Target Intestinal Macrophages for the Treatment of Inflammatory Bowel Disease.
Park B; Han G; Jin DY; Gil KC; Shin D; Lee J; Park JY; Jang H; Park D; Lee S; Kim K; Yang Y; Kim Y; Kim JS; Kim SH; Shim MK
ACS Nano; 2024 Jun; 18(25):16297-16311. PubMed ID: 38867457
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Evaluation of 5-ASA Colon-Specific Tablets Using Experimental-Induced Colitis Rat Animal Model.
Sawarkar SP; Deshpande SG; Bajaj AN; Nikam VS
AAPS PharmSciTech; 2015 Dec; 16(6):1445-54. PubMed ID: 26017284
[TBL] [Abstract][Full Text] [Related]
3. Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases.
Kandula M; Sunil Kumar KB; Palanichamy S; Rampal A
Int Immunopharmacol; 2016 Nov; 40():443-451. PubMed ID: 27716592
[TBL] [Abstract][Full Text] [Related]
4. 5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity.
Zhang S; Fu J; Dogan B; Scherl EJ; Simpson KW
J Antibiot (Tokyo); 2018 Nov; 71(11):950-961. PubMed ID: 30050110
[TBL] [Abstract][Full Text] [Related]
5. The colon targeting efficacies of mesalazine medications and their impacts on the gut microbiome.
McCoubrey LE; Seegobin N; Sangfuang N; Moens F; Duyvejonck H; Declerck E; Dierick A; Marzorati M; Basit AW
J Control Release; 2024 May; 369():630-641. PubMed ID: 38599548
[TBL] [Abstract][Full Text] [Related]
6. Using Theory To Extend the Scope of Azobenzene Drugs in Chemotherapy: Novel Combinations for a Specific Delivery.
Cerón-Carrasco JP; Jacquemin D
ChemMedChem; 2021 Jun; 16(11):1764-1774. PubMed ID: 33619857
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis.
Jung Y; Kim HH; Kim H; Kong H; Choi B; Yang Y; Kim Y
Eur J Pharm Sci; 2006 May; 28(1-2):26-33. PubMed ID: 16455235
[TBL] [Abstract][Full Text] [Related]
8. Combined Treatment with Hyaluronic Acid and Mesalamine Protects Rats from Inflammatory Bowel Disease Induced by Intracolonic Administration of Trinitrobenzenesulfonic Acid.
Chiu CT; Kuo SN; Hung SW; Yang CY
Molecules; 2017 May; 22(6):. PubMed ID: 28556814
[TBL] [Abstract][Full Text] [Related]
9. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
[TBL] [Abstract][Full Text] [Related]
10. Design and development of novel azo prodrugs using various permutations and combinations of 5- and 4-aminosalicylic acids for inflammatory bowel disease: a colon-targeted approach.
Suneela D; Gaurav V; Himanshu R
Inflamm Allergy Drug Targets; 2013 Oct; 12(5):328-40. PubMed ID: 24001333
[TBL] [Abstract][Full Text] [Related]
11. Modulation of N-glycosylation by mesalamine facilitates membranous E-cadherin expression in colon epithelial cells.
Khare V; Lang M; Dammann K; Campregher C; Lyakhovich A; Gasche C
Biochem Pharmacol; 2014 Jan; 87(2):312-20. PubMed ID: 24184502
[TBL] [Abstract][Full Text] [Related]
12. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
Klotz U
Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and molecular modeling studies of novel mesalamine linked coumarin for treatment of inflammatory bowel disease.
Rath B; Abul Qais F; Patro R; Mohapatra S; Sharma T
Bioorg Med Chem Lett; 2021 Jun; 41():128029. PubMed ID: 33839254
[TBL] [Abstract][Full Text] [Related]
14. [DDS preparations of drugs for inflammatory bowel disease].
Takada K
Nihon Rinsho; 1999 Nov; 57(11):2508-15. PubMed ID: 10572421
[TBL] [Abstract][Full Text] [Related]
15. Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease.
Dhaneshwar SS
World J Gastroenterol; 2014 Apr; 20(13):3564-71. PubMed ID: 24707139
[TBL] [Abstract][Full Text] [Related]
16. Effects of mesalamine (5-aminosalicylic acid) on bacterial gene expression.
Kaufman J; Griffiths TA; Surette MG; Ness S; Rioux KP
Inflamm Bowel Dis; 2009 Jul; 15(7):985-96. PubMed ID: 19202572
[TBL] [Abstract][Full Text] [Related]
17. Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease.
Bautzová T; Rabišková M; Lamprecht A
Drug Dev Ind Pharm; 2011 Sep; 37(9):1100-9. PubMed ID: 21417610
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of curcumin-loaded lipid-based nanocarriers in the treatment of inflammatory bowel disease.
Beloqui A; Memvanga PB; Coco R; Reimondez-Troitiño S; Alhouayek M; Muccioli GG; Alonso MJ; Csaba N; de la Fuente M; Préat V
Colloids Surf B Biointerfaces; 2016 Jul; 143():327-335. PubMed ID: 27022873
[TBL] [Abstract][Full Text] [Related]
19. Hemoglobin bio-adhesive nanoparticles as a colon-specific delivery system for sustained release of 5-aminosalicylic acid in the effective treatment of inflammatory bowel disease.
Vaezi Z; Asadzadeh Aghdaei H; Sedghi M; Mahdavian R; Molakarimi M; Hashemi N; Naderi-Manesh H
Int J Pharm; 2022 Mar; 616():121531. PubMed ID: 35121044
[TBL] [Abstract][Full Text] [Related]
20. 5-Aminosalicylic Acid Azo-Linked to Procainamide Acts as an Anticolitic Mutual Prodrug via Additive Inhibition of Nuclear Factor kappaB.
Kim W; Nam J; Lee S; Jeong S; Jung Y
Mol Pharm; 2016 Jun; 13(6):2126-35. PubMed ID: 27112518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
